


The Prostate in 3D



Your urologist chose the KOELIS Trinity[®], an advanced MRI and 3D Ultrasound guided prostate biopsy system, to perform your procedure.

The advantages of using this system include:

- Diagnosis guided by MRI images and targeted biopsy
- Improved cancer detection using 3D ultrasound and organ tracking software for accuracy
- Personalized treatment decisions based on biopsy results

The KOELIS Trinity[®] is a well-established biopsy technology that has been clinically validated in over 80 medical journals, used in more than 350,000 biopsy procedures to date, by over 300 hospitals.

Recent studies show MRI-guided prostate biopsy is effective for detecting higher-risk cancers and reducing unnecessary treatment of lower-risk cancers³.



Contact Us For More Information

www.koelis.com

116 Village Boulevard Suite 308, Princeton, NJ 08540

+1-800-579-9451

usa@koelis.com

www.linkedin.com/company/KOELIS/

www.youtube.com/KOELIS

www.facebook.com/KOELISSAS

[@KoelisBx](https://twitter.com/KoelisBx)

This brochure does not replace a professional medical opinion. Only your physician can diagnose and treat a medical problem.




The Benefits of MRI-Guided Prostate Biopsy



Why Have a Prostate Biopsy?

Prostate cancer is among the most common cancers according to the American Cancer Society, with approximately 1 in 8 men diagnosed during his lifetime. Early and accurate detection is key to treatment planning, and prostate biopsy is the only medical procedure in which prostate cancer can be diagnosed conclusively.¹

Approximately 1 in 8 men are diagnosed with prostate cancer during his lifetime.



KOELIS® has developed an innovative solution to capture precise locations of each biopsy core in a 3D map which can be used for future interventions.

Understanding Prostate Biopsy

A PSA blood test, digital rectal exam or other test may suggest signs of prostate cancer. To confirm or rule out those suspicions, a urologist performs a prostate biopsy. During a prostate biopsy, the urologist removes small tissue samples that will be further analyzed to establish the presence or absence of cancer.

Traditional vs. Targeted Biopsy

While some types of prostate cancer grow slowly, other types are aggressive and can spread quickly. That's why it is so important to focus on accurate diagnosis by pinpointing where abnormal cells are in the prostate, if any, and the size, extent, and aggressiveness of the cancer, also called the stage.²

The traditional prostate biopsy, known as blind biopsy, relies on using ultrasound only which is often limited by poor image quality and an ultrasound alone does not clearly identify suspicious areas for biopsy. A targeted MRI- guided prostate biopsy however, is a newer approach to biopsy that uses both MRI images and ultrasound to precisely target areas of concern during the procedure.

MRI- Guided Prostate Biopsy Process

Before the biopsy, you will have an MRI that creates high-resolution images of the prostate. During the biopsy, your urologist uses a specialized technology to overlay the MRI images with ultrasound, producing a 3D map or model of the prostate. The 3D map reflects the exact size and shape of your prostate, and it provides maximum accuracy for sample collection.



Treatment Management and Follow-up

The KOELIS Trinity® MRI-guided biopsy can increase the likelihood of accurate cancer detection and diagnosis, and lead to better treatment decisions for you. When the biopsy results are negative, or when cancer is found but is considered low risk, your urologist can continue monitoring your health using the original 3D map from your first biopsy, this is often called Active Surveillance. If the results show a higher risk cancer, your urologist will discuss the best course of action and treatment options.

References:

- <https://www.cancer.org/cancer/prostate-cancer/detection-diagnosis-staging/how-diagnosed.html> and <https://koelis.com/>
- <https://www.cancer.gov/about-cancer/diagnosis-staging/prognosis/tumor-grade-fact-sheet>
- Ahmed et al, Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.